Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 04, 2025 08:30 ET | Source: BioMedWire

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations

AUSTIN, Texas, Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S....
November 06, 2025 06:30 ET | Source: Bright Minds Biosciences

Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH

-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with...
October 23, 2023 09:00 ET | Source: Truveta

More than 50 organizations choose Truveta for the most complete, timely, and clean EHR data to study safety and effectiveness, improve patient care, and train medical AI

Bellevue, WASH., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Truveta announced today that it is partnering with more than 50 organizations in life sciences, healthcare, government, academic medical centers,...
July 27, 2021 06:30 ET | Source: CENTOGENE GmbH

CENTOGENE Appoints Patrice P. Denèfle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 27, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
June 25, 2021 06:30 ET | Source: CENTOGENE GmbH

CENTOGENE Announces Shareholders Approve All Resolutions at Annual General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 25, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
June 22, 2021 06:30 ET | Source: CENTOGENE GmbH

CENTOGENE Sets Mission to Enable the Cure of 100 Rare Diseases Within the Next 10 Years

Company outlines significant value creation potential to contribute to the diagnosis of rare diseases and to enable the development of novel therapeuticsFocuses on leveraging its unique rare...
June 02, 2021 06:31 ET | Source: CENTOGENE GmbH

CENTOGENE Initiates EFRONT Study to Identify Patients With Genetic Forms of Frontotemporal Dementia

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 02, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
June 01, 2021 06:30 ET | Source: CENTOGENE GmbH

CENTOGENE Launches NEW CentoXome® - An Enhanced Whole Exome Sequencing Solution

World leader and trusted partner in rare diseases releases enhanced Whole Exome Sequencing (WES) solution to improve diagnosis in complex and unsolved patient casesNEW CentoXome® provides...
May 18, 2021 06:30 ET | Source: CENTOGENE GmbH

CENTOGENE Appoints Michael Motz as Chief Commercial Officer, Pharmaceuticals

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 18, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...
May 10, 2021 06:30 ET | Source: CENTOGENE GmbH

CENTOGENE Extends Global Parkinson’s Disease Study

Providing patients with genetic testing designed to accelerate the diagnosis and personalized treatment of Parkinson’s disease (PD) The Rostock International Parkinson's Disease (ROPAD) Study aims to...